deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03952234

L-Citrulline Dose Finding Safety Study in MELAS

Phase-1, Dose Finding and Safety Study on L- Citrulline Treatment of Nitric Oxide Deficiency in MELAS

Sponsor: Baylor College of Medicine

Conditions MELAS Syndrome
Interventions L-Citrulline
Updated 10 times since 2019 Last updated: Jun 24, 2024 Started: Apr 22, 2021 Primary completion: Apr 30, 2024 Completion: Jun 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on MELAS Syndrome, this trial is completed. The trial is conducted by Baylor College of Medicine and has accumulated 10 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

The human body is made of many cells and each cell contains many mitochondria. Mitochondria are called the powerhouses of the cell, because they produce the energy needed for a cell to be healthy and function the way it is meant to. Diseases of the mitochondria affect the way the tissues and cells of the body make and use energy, and can affect almost all the different organs of the body like the brain and the muscles. MELAS syndrome is one of the mitochondrial diseases; patients with this disease have different complications including stroke like episodes, headache, muscle weakness, fatigue, and hearing loss. One of the factors contributing to complications seen in patients with MELAS syndrome, in particular the stroke like episodes, is decreased amount of an element called nitric oxide. This element is made in the bodies from an amino acid called arginine. Amino acids are the building blocks of proteins. Proteins make the muscles in the bodies, and they are present in meat, chicken and fish. In this study, the highest acceptable dose of an amino acid called citrulline will be established in participants who have a mitochondrial disorder. Previous research conducted by several groups including Baylor College...

The human body is made of many cells and each cell contains many mitochondria. Mitochondria are called the powerhouses of the cell, because they produce the energy needed for a cell to be healthy and function the way it is meant to.

Diseases of the mitochondria affect the way the tissues and cells of the body make and use energy, and can affect almost all the different organs of the body like the brain and the muscles.

MELAS syndrome is one of the mitochondrial diseases; patients with this disease have different complications including stroke like episodes, headache, muscle weakness, fatigue, and hearing loss. One of the factors contributing to complications seen in patients with MELAS syndrome, in particular the stroke like episodes, is decreased amount of an element called nitric oxide. This element is made in the bodies from an amino acid called arginine. Amino acids are the building blocks of proteins. Proteins make the muscles in the bodies, and they are present in meat, chicken and fish.

In this study, the highest acceptable dose of an amino acid called citrulline will be established in participants who have a mitochondrial disorder. Previous research conducted by several groups including Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in patients affected with MELAS.

The lack of nitric oxide could cause constriction of blood vessels in the brain making it easier for these patients to have a metabolic stroke. The amino acid citrulline is a foundation for nitric oxide. In earlier studies, the investigator has found that there is more production of nitric oxide in the body when participants affected with MELAS take L-citrulline.

Status Flow

~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshotNot Yet Recruiting~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshotNot Yet Recruiting~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2021 – ~May 2021 · 3 months · monthly snapshotNot Yet Recruiting~May 2021 – ~May 2022 · 12 months · monthly snapshotRecruiting~May 2022 – ~Aug 2023 · 15 months · monthly snapshotRecruiting~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

10 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

    Status: RecruitingCompleted

  3. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. May 2022 — Aug 2023 [monthly]

    Recruiting PHASE1

  5. May 2021 — May 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet RecruitingRecruiting

Show 5 earlier versions
  1. Feb 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

  2. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE1

  3. Aug 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

  4. Feb 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1

  5. Jun 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
  • Columbia University
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • University of South Florida
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations